Details for Patent: 12,156,940

Which drugs does patent 12,156,940 protect, and when does it expire?

Patent 12,156,940 protects EXPAREL and is included in one NDA.

This patent has seven patent family members in seven countries.

Summary for Patent: 12,156,940

Title:	Manufacturing of bupivacaine multivesicular liposomes
Abstract:	Embodiments of the present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs). Batches of bupivacaine MVLs prepared by the new process have high yields, improved stabilities, and desired particle size distributions.
Inventor(s):	Eran Levy, Jeffrey S. Hall, John J. Grigsby, Jr.
Assignee:	Pacira Pharmaceuticals Inc
Application Number:	US18/761,863
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,156,940
Patent Claim Types: see list of patent claims	Composition; Dosage form;

Drugs Protected by US Patent 12,156,940

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pacira Pharms Inc	EXPAREL	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	022496-001	Oct 28, 2011		RX	Yes	Yes			Y
Pacira Pharms Inc	EXPAREL	bupivacaine	INJECTABLE, LIPOSOMAL;INJECTION	022496-002	Oct 28, 2011		RX	Yes	Yes			Y

International Family Members for US Patent 12,156,940

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2025208569
European Patent Office	4673147
United Kingdom	2644950
Japan	2026520796